MAGEF1: A Potential Drug Target for Various Diseases (G64110)

Target Name: MAGEF1

NCBI ID: G64110

MAGEF1

MAGEF1: A Potential Drug Target for Various Diseases

MAGEF1, a gene product of the MAGE family, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MAGEF1 is a transmembrane protein that plays a crucial role in the immune system and has been shown to be involved in the development and progression of various diseases.

The MAGE family is a subset of the T cell receptor (TCR) family and is characterized by the presence of a variable region in the extracellular domain of the protein that contains a leucine-rich repeat. MAGEF1 is a member of the MAGE family and has a similar structure to other MAGE proteins, including MAGE-A2, MAGE-B, and MAGE-C. MAGEF1 is expressed in various tissues and cells throughout the body and has been shown to be involved in various immune responses, including inflammation and antiviral defense.

One of the key functions of MAGEF1 is its role in the regulation of T cell function. MAGEF1 has been shown to interact with the transcription factor T-cell factor (TF), which is involved in the development and activation of T cells. MAGEF1 has been shown to play a role in the regulation of T cell proliferation, differentiation, and selection, and has been shown to be involved in the development of various T cell-mediated diseases, including cancer.

In addition to its role in T cell regulation, MAGEF1 has also been shown to be involved in the regulation of inflammation and immune tolerance. MAGEF1 has been shown to play a role in the regulation of inflammation, including the regulation of cytokine production and the control of immune tolerance. MAGEF1 has also been shown to be involved in the development and progression of various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis.

MAGEF1 has also been shown to be involved in the regulation of cell survival and metabolism. MAGEF1 has been shown to play a role in the regulation of cell survival and metabolism, including the regulation of cell apoptosis and the control of cell proliferation. MAGEF1 has also been shown to be involved in the regulation of cellular signaling pathways, including the regulation of the PI3K/Akt signaling pathway.

In conclusion, MAGEF1 is a transmembrane protein that is involved in various immune and non-immune processes throughout the body. The MAGE family is a subset of the TCR family and has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MAGEF1 is a potential drug target and biomarker for these diseases and has the potential to be a valuable tool in the development of new therapies for these conditions.

Protein Name: MAGE Family Member F1

Functions: Enhances ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin ligases. Proposed to act through recruitment and/or stabilization of the E2 ubiquitin-conjugating enzyme at the E3:substrate complex. MAGEF1-NSMCE1 ubiquitin ligase complex promotes proteasomal degradation of MMS19, a key component of the cytosolic iron-sulfur protein assembly (CIA) machinery. Down-regulation of MMS19 impairs the activity of several DNA repair and metabolism enzymes such as ERCC2/XPD, FANCJ, RTEL1 and POLD1 that require iron-sulfur clusters as cofactors. May negatively regulate genome integrity by inhibiting homologous recombination-mediated double-strand break DNA repair (PubMed:29225034)

The "MAGEF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets